Estimating the Prevalence of Opioid Diversion by "Doctor Shoppers" in the United States

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  McDonald, Douglas C ^a   Carlson, Kenneth E ^a  

^a ABT ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CODEINE; DEXTROPROPOXYPHENE; DIHYDROCODEINE; FENTANYL; HYDROCODONE; METHADONE; OPIATE; OXYCODONE; OXYMORPHONE; TRAMADOL;

ARTICLE; CONTROLLED STUDY; DRUG MISUSE; MATHEMATICAL MODEL; OPIATE ADDICTION; POPULATION MODEL; PRESCRIPTION; PREVALENCE; UNITED STATES;

HUMANS; OPIOID-RELATED DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; UNITED STATES;

EID: 84880424413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069241     Document Type: Article

References (65)

1. Substance Abuse and Mental Health Services Administration (2003) Emergency Department Trends from the Drug Abuse Warning Network, Final Estimates 1995-2002. Rockville, MD: Office of Applied Studies.
2. Substance Abuse and Mental Health Services Administration (2011) Drug Abuse Warning Network, 2009: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration.
3. Substance Abuse and Mental Health Services Administration (2009) Treatment Episode Data Set (TEDS) Highlights- 2007 National Admissions to Substance Abuse Treatment Services. Rockville, MD: Office of Applied Studies.
4. Substance Abuse and Mental Health Services Administration (2013) The DAWN Report: Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Rockville, MD: Center for Behavioral Health Statistics and Quality.
5. Substance Abuse and Mental Health Services Administration (2012) Treatment Episode Data Set (TEDS): 2000-2010. National Admissions to Substance Abuse Treatment Services. S-61 ed. Rockville, MD: Center for Behavioral Health Statistics and Quality.
6. Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM (2011) Drug poisoning deaths in the United States, 1980-2008. Hyattsville, MD: National Center for Health Statistics.
7. Paulozzi LJ, Jones CM, Mack KA, Rudd RA (2011) Vital Signs: Overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 60.
8. Substance Abuse and Mental Health Services Administration (2010) Results from the 2009 National Survey on Drug Use and Health: Volume II. Technical Appendices and Selected Prevalence Tables. Rockville, MD: Office of Applied Studies.
9. United Nations Office on Drugs and Crime (2011) World Drug Report 2011 New York City: United Nations.
10. Drug Enforcement Administration (1997-2006) Automation of Reports and Consolidated Orders System (ARCOS) Retail Drug Summary. Office of Diversion Control.
11. Drug Enforcement Administration (2008-2011) Automation of Reports and Consolidated Orders System (ARCOS) Retail Summary Reports. Office of Diversion Control.
12. McDonald D, Carlson K, Izrael D, (2012) Geographic variation in opioid prescribing in the U.S. J Pain. 13: 988-996.
13. Paulozzi LJ, Ryan GW, (2006) Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 31: 506-511.
14. Institute of Medicine (2011) Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press.
15. Campbell J (1996) Presidential Address, American Pain Society.
16. Fishman SM, Papazian JS, Gonzalez S, Riches PS, Gilson A, (2004) Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Pain Med 5: 309-324.
17. Van Zee A, (2009) The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health 99: 221-227.
18. Manchikanti L, Singh V, Bakhit CE, Fellows B, (2000) Interventional techniques in the management of chronic pain: Part 1.0. Pain Physician 3: 7-42.
19. Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer TR, et al. (2006) Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 9: 1-39.
20. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, et al. (2008) Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 11: S5-S62.
21. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, et al. (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10: 113-130.
22. Federation of State Medical Boards of the United States I (2004) Model policy for the use of controlled substances for the treatment of pain. Euless, Texas.
23. Federation of State Medical Boards of the United States I (1998) Model guidelines for the use of controlled substances for the treatment of pain. Euless, Texas.
24. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, et al. (2012) American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I-evidence assessment. Pain Physician 15: S1-65.
25. Fishman SM (2007) Responsible Opioid Prescribing: A Physician's Guide. Washington, DC: Waterford Life Sciences.
26. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, et al. (2003) College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 69: 215-232.
27. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, et al. (2008) Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone). Pain Pract 8: 287-313.
28. Substance Abuse and Mental Health Services Administration (2011) Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration.
29. Lembke A, (2012) Why doctors prescribe opioids to known opioid abusers. N Engl J Med 367: 1580-1581.
30. Peirce GL, Smith MJ, Abate MA, Halverson J, (2012) Doctor and Pharmacy Shopping for Controlled Substances. Medical Care 50: 7.
31. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, et al. (2008) Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 300: 2613-2620.
32. Wilsey BL, Fishman SM, Gilson AM, Casamalhuapa C, Baxi H, et al. (2010) Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants, and anorectics. Drug Alcohol Depend 112: 99-106.
33. Cepeda M, Fife D, Mastrogiovanni G, Henderson CS, (2012) Assessing opiod shopping behaviour: a large cohort study from a medication dispensing database in the US. Drug Saf 35: 9.
34. Katz N, Panas L, Kim M, Audet AD, Bilansky A, et al. (2010) Usefulness of prescription monitoring programs for surveillance-analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006. Pharmacoepidemioloy and Drug Safety 19: 115-123.
35. Cepeda M, Fife D, Mastrogiovanni G, Henderson CS (2012) Opioid Shopping Behavior: How Often, How Soon, Which Drugs, and What Payment Method. J Clin Pharmacol.
36. Buurma H, Bouvy ML, Smet PAGMD, Floor-Schreudering A, Leufken HGM, et al. (2008) Prevalence and determinants of pharmacy shopping behaviour. Journal of Clinical Pharmacy and Therapeutics 33: 17-23.
37. Pradel V, Frauger E, Thirion X, Ronfle E, Lapierre V, et al. (2009) Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiology and Drug Safety 18: 36-43.
38. Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, et al. (2006) Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res 41: 837-855.
39. Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, et al. (2006) Correction to "Geographic Variation in the Prescription of Schedule II Opioid Analgesics among Outpatients in the United States". Health Serv Res 41: 856-859.
40. Von Korff M, Dunn KM, (2008) Chronic pain reconsidered. Pain 138: 267-276.
41. McLachlan G, Peel D (2000) Finite Mixture Models. New York: John Wiley & Sons, Inc.
42. Deb P (2012) FMM: Stata module to estimate finite mixture models. EconPapers. Örebro, Sweden: Örebro University School of Business.
43. Cicero TJ, Surratt H, Inciardi JA, Munoz A, (2007) Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf 16: 827-840.
44. Substance Abuse and Mental Health Services Administration (2012) Results from the 2010 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Center for Behavioral Health Statistics and Quality.
45. National Alliance for Model State Drug Laws (2013) States That Require an ID from a Recipient Prior to Dispensing Prescriptions. Santa Fe, NM: The National Alliance for Model State Drug Laws.
46. Rigg KK, March SJ, Inciardi JA, (2010) Prescription drug abuse & diversion: role of the pain clinic. J Drug Issues 40: 681-702.
47. Parente ST, Kim SS, Finch MD, Schloff LA, Rector TS, et al. (2004) Identifying controlled substance patterns of utilization requiring evaluation using administrative claims data. Am J Manag Care 10: 783-790.
48. White AG, Birnbaum HG, Schiller M, Tang J, Katz NP, (2009) Analytic models to identify patients at risk for prescription opioid abuse. Am J Manag Care 15: 897-906.
49. Wilsey BL, Fishman SM, Gilson AM, Casamalhuapa C, Baxi H, et al. (2010) Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants, and anorectics. Drug Alcohol Depend 112: 99-106.
50. Wilsey BL, Fishman SM, Gilson AM, Casamalhuapa C, Baxi H, et al. (2011) An analysis of the number of multiple prescribers for opioids utilizing data from the California Prescription Monitoring Program. Pharmacoepidemiol Drug Saf 20: 1262-1268.
51. US Congress (2001) FY 2002 U.S. Department of Justice Appropriations Act (Public Law 107-77).
52. US Congress (2005) National All Schedules Prescription Electronic Reporting Act of 2005, Public Law 109-60, 42 U.S.C 280g-3.
53. Manchikanti L, Whitfield E, Pallone F, (2005) Evolution of the National All Schedules Prescription Electronic Reporting Act (NASPER): a public law for balancing treatment of pain and drug abuse and diversion. Pain Physician 8: 335-347.
54. The MITRE Corporation (2012) Enhancing Access to Prescription Drug Monitoring Programs Using Health Information Technology: Work Group Recommendations. McLean, VA.
55. National Alliance For Model State Drug Laws (2012) States That Require Prescribers And/Or Dispensers To Access PMP Database In Certain Circumstances. Santa Fe, NM: The National Alliance For Model State Drug Laws.
56. Drug Enforcement Administration. Controlled Substances: Aggregate Production Quotas. Federal Register.
57. Food and Drug Administration, Drug Safety and Risk Management Advisory Committee (2012) FDA Briefing Document. Washington, DC: Department of Health and Human Services.
58. New York State Office of the Attorney General (2013) A.G. Schneiderman Alerts Medical Professionals To New Hydrocodone Rule Change Under Rx Drug Law. Albany, NY.
59. Simoni-Wastila L, Ross-Degnan D, Mah C, Gao X, Brown J, et al. (2004) A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in medicaid patients with chronic psychiatric and neurologic disorders. Clin Ther 26: 322-336.
60. Office of National Drug Control Policy (2012) ADAM II: 2011 Annual Report, Arrestee Drug Abuse Monitoring Program II. Washington, DC: Office of National Drug Control Policy, Executive Office of the President.
61. Substance Abuse and Mental Health Services Administration (2011) The DAWN Report: Illicit Drug-Related Emergency Department Visits in Metropolitan Areas of the United States: 2009. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality.
62. Rigg KK, Kurtz SP, Surratt HL, (2012) Patterns of prescription medication diversion among drug dealers. Drugs (Abingdon Engl) 19: 144-155.
63. Wolfert MZ, Gilson AM, Dahl JL, Cleary JF, (2010) Opioid analgesics for pain control: Wisconsin physicians' knowledge, beliefs, attitudes, and prescribing practices. Pain Med 11: 425-434.
64. Lebovits AH, Florence I, Bathina R, Hunko V, Fox MT, et al. (1997) Pain knowledge and attitudes of healthcare providers: practice characteristic differences. Clin J Pain 13: 237-243.
65. Manchikanti L, Atluri S, Trescot AM, Giordano J, (2008) Monitoring Opioid Adherence in Chronic Pain Patients: Tools, Techniques, and Utility. Pain Physician 79: 1031-1034.